Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.

Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY.

Am J Clin Pathol. 2005 Aug;124(2):282-7.

PMID:
16040301
2.

Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions.

Liang S, Yao J, Bourne PA, diSant'Agnese PA, Huang J, Lei JY.

Am J Clin Pathol. 2004 Nov;122(5):747-51.

PMID:
15491971
3.

Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.

Hanas JS, Lerner MR, Lightfoot SA, Raczkowski C, Kastens DJ, Brackett DJ, Postier RG.

Cancer. 1999 Sep 1;86(5):756-63.

PMID:
10463972
4.
5.

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.

Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28.

PMID:
19638963
6.

An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.

Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z.

Am J Surg Pathol. 2009 Apr;33(4):521-5. doi: 10.1097/PAS.0b013e31818aada9.

PMID:
19047899
7.

Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions.

Feng W, Zhou Z, Peters JH, Khoury T, Zhai Q, Wei Q, Truong CD, Song SW, Tan D.

Arch Pathol Lab Med. 2011 Aug;135(8):1024-31. doi: 10.5858/2009-0617-OAR2.

PMID:
21809994
8.

Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.

Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2006 Apr;30(4):423-35.

PMID:
16625087
9.

Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.

Abraham SC, Wang H, Wang KK, Wu TT.

Am J Surg Pathol. 2008 Jul;32(7):1068-74. doi: 10.1097/PAS.0b013e318160c579.

PMID:
18496141
10.

Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.

Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R.

Cancer. 2007 Feb 15;109(4):668-74.

11.

CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

Hansel DE, Dhara S, Huang RC, Ashfaq R, Deasel M, Shimada Y, Bernstein HS, Harmon J, Brock M, Forastiere A, Washington MK, Maitra A, Montgomery E.

Am J Surg Pathol. 2005 Mar;29(3):390-9.

PMID:
15725809
12.

Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.

Hermann B, Li Y, Ray MB, Wo JM, Martin RC 2nd.

Arch Surg. 2005 Dec;140(12):1204-9; discussion 1209.

PMID:
16365243
13.

Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions.

Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M.

Am J Clin Pathol. 2002 Jul;118(1):60-6.

PMID:
12109857
14.

Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5. doi: 10.1158/1055-9965.EPI-07-2734.

15.

Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.

Sarbia M, Bektas N, Müller W, Heep H, Borchard F, Gabbert HE.

Cancer. 1999 Dec 15;86(12):2597-601.

PMID:
10594854
16.

Metabolomics study of esophageal adenocarcinoma.

Zhang J, Liu L, Wei S, Nagana Gowda GA, Hammoud Z, Kesler KA, Raftery D.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):469-75, 475.e1-4. doi: 10.1016/j.jtcvs.2010.08.025. Epub 2010 Sep 28.

17.

Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.

Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y.

Acta Neuropathol. 2005 Mar;109(3):294-8. Epub 2004 Dec 31.

PMID:
15627206
18.

Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.

Asthana N, Mandich D, Ligato S.

Am J Surg Pathol. 2008 Oct;32(10):1581-5. doi: 10.1097/PAS.0b013e3181753aa6.

PMID:
18724240
19.

Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.

Geddert H, Heep HJ, Gabbert HE, Sarbia M.

Cancer. 2002 Jan 1;94(1):212-8.

20.

Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.

van Dekken H, Hop WC, Tilanus HW, Haringsma J, van der Valk H, Wink JC, Vissers KJ.

Am J Clin Pathol. 2008 Nov;130(5):745-53. doi: 10.1309/AJCPO31THGVEUIDH.

PMID:
18854267

Supplemental Content

Support Center